Abstract: A method for identifying a subject having at least an indication or predisposition for developing inflammatory bowel disease or colorectal cancer based upon the presence of Salmonella AvrA protein, nucleic acids and antibodies is provided as is a method for treating Salmonella infection-related colorectal cancer using a Wnt1 agonist.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
October 11, 2022
Assignee:
The Board of Trustees of the University of Illinois
Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.
Type:
Grant
Filed:
February 4, 2011
Date of Patent:
September 27, 2022
Assignee:
Astute Medical, Inc.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: Provided are methods, compositions, kits and the like, for diagnosing and differentiating patients with systemic juvenile idiopathic arthritis (sJIA) from patients with Kawasaki disease (KD) and other febrile illnesses.
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
September 20, 2022
Assignee:
ASCENDANT DIAGNOSTICS, LLC
Inventors:
Patricia Beckmann, Lindsay Rutherford, Anna Daily, Omid Moghadam, Elizabeth Mellins
Abstract: The present invention provides a method of making an assay device for conducting an assay to detect a concentration of an analyte in a sample fluid. The assay devices would typically have a substantially planar surface having a series of site specific immobilized calibration spot arrays containing pre-determined quantities of the analyte printed thereon. In addition, a series of site specific immobilized test spot arrays, including capture antibody for binding the analyte protein is printed on the assay device. The method involves first modifying the planar surface to provide hydrophobic binding sites, hydrophilic linking and covalent bonding sites. Then the method requires printing the series of site specific immobilized test spot arrays and the series of site specific immobilized calibration spot arrays on the substantially planar surface.
Type:
Grant
Filed:
July 20, 2005
Date of Patent:
August 23, 2022
Assignee:
SQI DIAGNOSTICS SYSTEMS INC.
Inventors:
Peter Lea, Thomas G. Ewart, Stuart X. Carmichael, Claude Ricks
Abstract: The present invention leverages the techniques for expansion microscopy (ExM) to provide improved high-throughput super-resolution whole-organ imaging methodology to image protein architectures over whole organs with nanoscale resolution by using high-throughput microscopes in combination with samples that have been iteratively expanded more than once, in a method referred to herein as “iterative expansion microscopy” (iExM). In the ExM method, biological samples of interest are permeated with a swellable material that results in the sample becoming embedded in the swellable material, and then the sample can be expanded isotropically in three dimensions The process of iteratively expanding the samples can be applied to samples that have been already expanded using ExM techniques one or more additional times to iteratively expand them such that, for example, a 5-fold expanded specimen can be expanded again 3- to 4-fold, resulting in as much as a 17- to 19-fold or more linear expansion.
Type:
Grant
Filed:
April 14, 2016
Date of Patent:
August 9, 2022
Assignee:
Massachusetts Institute of Technology
Inventors:
Edward Stuart Boyden, Jae-Byum Chang, Fei Chen, Paul Warren Tillberg
Abstract: A method for detecting and quantifying allergen components of a substance is described herein. A method can include obtaining an Ig sample derived from two or more individuals, and one or more capillaries comprising allergenic biologics adhered thereto. The Ig sample can be applied to the one or more capillaries and allergen component and molecules that has bound with the Ig sample, can be detected in the one or more capillaries. A molecular weight and/or frequency of appearance, an isoelectric charge and/or frequency of appearance, a molecular functional group and/or frequency of appearance or a combination thereof, of the allergen component can be recorded. Furthermore, methods for determining the minimum and maximum concentrations of the detected allergen components for pre-determined platforms, formulating an allergen product using the determined concentration ranges and applying the allergen product to result an effective assay are described.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
August 9, 2022
Inventors:
Sam Wei Polly Chan, Elaine Taine, Scott Vande Wetering, John Li, Charles Lee, Lin Qian
Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.
Type:
Grant
Filed:
July 9, 2013
Date of Patent:
August 2, 2022
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
Abstract: Objects of the present invention are to find a marker by which progression of arteriosclerosis can be directly grasped, to thereby provide motivation for prevention or treatment of arteriosclerosis itself, and to provide means for accurately grasping condition of arteriosclerosis-related disease including arteriosclerotic disease. The invention provides a method for acquiring data on progression of arteriosclerosis, the method including determining a level of an antibody against SH3BP5 protein or a part thereof in a body fluid sample collected from a biological body, and a data acquisition kit for performing the data acquisition method.
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
July 19, 2022
Assignees:
FUJIKURA KASEI CO., LTD., National University Corporation Chiba University
Inventors:
Hideyuki Kuroda, Rika Nakamura, Go Tomiyoshi, Takaki Hiwasa
Abstract: The present invention relates to a method for detecting a target substance that is useful for detection of a glycoprotein and the like comprising a specific sugar chain, a reagent for detecting a target substance, a carrier and a method for manufacturing the carrier.
Abstract: The present invention intends to provide an immunochromatographic test piece that makes it possible to achieve both highly sensitive detection of a substance to be detected and a simple test piece structure, which are usually difficult to be made compatible with each other.
Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.
Type:
Grant
Filed:
October 22, 2015
Date of Patent:
June 28, 2022
Assignee:
The George Washington University A Congressionally
Chartered Not-For-Profit Corporation
Inventors:
Lakhmir S. Chawla, Timothy A. McCaffrey
Abstract: Matrix-assisted methods and compositions, including those based on solutions containing low melting agarose, to prepare intact organs and other samples for super resolution imaging by microscopy, and more particularly, lightsheet microscopy.
Abstract: Systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The systems includes at least one support structure, at least one small primary support portion containing at least one molecule covalently bound to a visual colloidal marker, a plurality of secondary support portions comprising secondary binding compounds that are covalently bound to the support portions and chemically active, at least one pH litmus indicator, at least one pH strip, a buffer for lateral flow on the porous membrane support that allows preservation and activity of binding compounds.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
May 3, 2022
Assignee:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diaposis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, it a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.
Type:
Grant
Filed:
January 30, 2018
Date of Patent:
December 14, 2021
Assignee:
MEDIZINISCHE HOCHSCHULE HANNOVER
Inventors:
Niklas Thomas Baerlecken, Torsten Witte
Abstract: The invention is an ex vivo method for early detection of acute kidney injury in critical patients, which includes the measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers. These measurements are obtained from a venous blood sample or urine, and allow the determination of the following indicators: 1=([FGF23]p×[EPO]p); 2=([FGF23]p/[Klotho]p); 3=([EPO]p)/[Klotho]p); 4=([FGF23]p×[EPO]p)/[Klotho]p); where [X]p is defined as the plasma level of a specific molecule (X) which includes fibroblast growth factor 23 (FGF23), klotho (KL) or erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is equal or higher than a cut-off point (10 U), the indicator and/or indicators allow the identification of patients with high risk of developing AKI, with a high sensitivity/specificity.
Type:
Grant
Filed:
October 14, 2016
Date of Patent:
November 23, 2021
Assignee:
UNIVERSIDAD DE CHILE
Inventors:
Luis Alejandro Toro-Cabrera, Luis Fernando Michea-Acevedo
Abstract: The present invention provides an anti-human hemoglobin monoclonal antibody or an antibody kit for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample with ease, and an insoluble carrier particle to which the monoclonal antibody is immobilized, and a measurement reagent and a measurement method for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample using the same. The anti-human hemoglobin monoclonal antibody of the present invention does not react to free hemoglobin or free haptoglobin which is not formed in a complex, but specifically reacts to a hemoglobin-haptoglobin complex when the antibody is immobilized to an insoluble carrier particle and used.
Abstract: A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curves different from the other of the plurality of response curves, storing a combined response curve resulting from a summation of the plurality of response curves, exposing the plurality of test sites to a sample having a concentration of a molecule of interest, obtaining a plurality of quantitation signals, each of the plurality of quantitation signals associated with one of the plurality of test sites, associating a summation of the plurality of quantitation signals with the stored combined response curve, and generating a signal related to the concentration of the molecule of interest based upon the association.
Type:
Grant
Filed:
February 5, 2014
Date of Patent:
October 12, 2021
Assignee:
Robert Bosch GmbH
Inventors:
Sam Kavusi, Michaela Laupheimer, Christoph Lang
Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
Type:
Grant
Filed:
December 10, 2013
Date of Patent:
August 31, 2021
Assignees:
SEATTLE CHILDREN'S HOSPITAL, The University of Queensland
Inventors:
Yadveer Grewal, Gerard A. Cangelosi, Muhammad J. A. Shiddiky, Matt Trau
Abstract: The present invention relates to a sensor for an electronic tongue or nose for analysing a sample or detecting a target. The sensor comprises a support, on one surface of which a plurality of sensitive areas are located, each sensitive area comprising at least one receptor and being capable of transmitting a measurable signal generated by the interaction of at least one constituent of the sample or one target with at least one receptor. The sensor is characterised in that it comprises at least three sensitive areas that differ from one another in terms of their respective receptor compositions, at least one of the sensitive areas comprising a mixture of at least two different receptors, while the two other sensitive areas each comprise at least one of the two receptors.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
August 10, 2021
Assignees:
Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique, Universite Paris-Sud
Inventors:
Thierry Livache, Arnaud Buhot, David Bonnaffe, Yanxia Hou-Broutin